Ignite Creation Date:
2024-10-26 @ 3:35 PM
Last Modification Date:
2024-10-26 @ 3:35 PM
Study NCT ID:
NCT06512311
Status:
RECRUITING
Last Update Posted:
None
First Post:
2024-07-10
Brief Title:
Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening
Sponsor:
None
Organization:
None
Study Overview
Official Title:
Personalized Targeted Glioblastoma Therapies by ex Vivo Drug Screening Advanced Brain Tumor TheRApy Clinical Trial ATTRACT
Status:
RECRUITING
Status Verified Date:
2024-07
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
ATTRACT
Brief Summary:
Patient derived cell line PDC -based drug screening will be applied to formulate a personalized treatment approach
Detailed Description:
Patient derived cell line PDC -based drug screening will be applied to formulate a personalized treatment approach Patients will be randomized between the investigational group receiving in addition to standard histology analysis also the PDC-based drug screening and the standard group receiving only standard histology analysis Outcome results will be compared in a randomized interventional clinical performance study The PDC-based drug screening will be performed only in accordance with the approved Performance Study Plan on subjects who have signed an informed consent form
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None